Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis

Teclegiorgis Gebremariam, Nathan P. Wiederhold, Abdullah Alqarihi, Priya Uppuluri, Nkechi Azie, John E. Edwards, Ashraf S. Ibrahim

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Objectives: Previously we demonstrated the benefit of isavuconazole in treating murine mucormycosis due to Rhizopus. We wanted to determine the efficacy of isavuconazole in treating murine mucormycosis caused by Mucor, the second most common cause of the disease. Furthermore, because we previously determined that Rhizopus possesses the target enzyme for echinocandins and micafungin has activity against murine mucormycosis, we compared the activity of combination therapy (isavuconazole+micafungin) with placebo, either drug alone or standard therapy of liposomal amphotericin B (LAmB) in treating pulmonary murine mucormycosis caused by Rhizopus delemar. Methods: In vitro susceptibility to isavuconazole of Mucorales was evaluated using the CLSI M38-A2 method. Immunosuppressed mice were intratracheally infected with either Mucor circinelloides or R. delemar. Treatment with isavuconazole (orally), micafungin (intraperitoneally), a combination of both or LAmB (intravenously) was compared, with survival and tissue fungal burden serving as primary and secondary endpoints, respectively. Results: Isavuconazole was as effective as LAmB in prolonging survival of mice infected with M. circinelloides. Against R. delemar-induced mucormycosis, all monotherapy treatments significantly improved survival of mice versus placebo without showing superiority over one another. However, LAmB was superior in lowering fungal burden in target organs. Although combination therapy of isavuconazole+micafungin did not enhance survival of mice over monotherapy, antagonism was not detected between the two drugs. Conclusion: Isavuconazole is effective in treating pulmonarymurinemucormycosis due toMucor. In addition, combination therapy of isavuconazole+micafungin does not demonstrate synergy and it is not antagonistic against Rhizopus-induced mucormycosis.

Original languageEnglish (US)
Pages (from-to)462-466
Number of pages5
JournalJournal of Antimicrobial Chemotherapy
Issue number2
StatePublished - Feb 2017

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology


Dive into the research topics of 'Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis'. Together they form a unique fingerprint.

Cite this